Trudy
Laufzeit: 01.01.2021 - 31.12.2029
imported
Kurzfassung
TRUDY/ DESTINY Breast05 (GBG 103):T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
Laufzeit: 01.01.2021 - 31.12.2029
TRUDY/ DESTINY Breast05 (GBG 103):T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy